Patents Assigned to Pharming
  • NOVEL METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN
    Publication number: 20170369504
    Abstract: The present invention provides a novel method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase, and novel intermediates used in the method.
    Type: Application
    Filed: December 30, 2015
    Publication date: December 28, 2017
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jong Ouk BAEK, Jae Hyuk JUNG, Ho Seok KIM, Tae Hee HA, Kwee Hyun SUH
  • COMPOSITE CAPSULES COMPRISING RALOXIFENE, AND VITAMIN D OR ITS DERIVATIVES
    Publication number: 20170368049
    Abstract: A composite capsule and a method of preparing the same are provided. The composite capsule includes: a raloxifene separate layer including raloxifene or a pharmaceutically acceptable salt thereof; and a vitamin D separate layer including vitamin D or a derivative thereof, wherein the raloxifene separate layer and the vitamin D separate layer are separated from one another in the composite capsule.
    Type: Application
    Filed: January 28, 2016
    Publication date: December 28, 2017
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Young Hun KIM, Taek Kwan KWON, Jin Young PARK, Seung Bin YOUN, Jae Hyun PARK, Jong Soo WOO, Yong Il KIM
  • COMPOSITION CONTAINING EXTRACT OR FRACTION OF GENUS JUSTICIA PLANT
    Publication number: 20170360862
    Abstract: The present invention relates to a pharmaceutical composition, food composition and cosmetic composition for preventing, treating, or improving allergic diseases comprising extract or fraction of a plant of the Justicia genus as an active ingredient. The extract or a fraction of a plant of the Justicia genus according to the present invention can inhibit IgE antibody secretion and the degranulation of mast cells and basophils, and exhibits an excellent anti-allergic effect, and thus can effectively prevent, treat, or improve allergic diseases.
    Type: Application
    Filed: October 16, 2015
    Publication date: December 21, 2017
    Applicant: DONG WHA PHARM. CO., LTD.
    Inventors: Joo Byoung Yoon, Hyun Yong Lee, Ji Hyun Youm, Kwang Hyun Kim, Ji Hyun Jeon, Hwan Bong Chang, Yun Ha Hwang, Seung Kyoo Seong, Dong Rack Choi
  • GLUCAGON DERIVATIVES WITH IMPROVED STABILITY
    Publication number: 20170360892
    Abstract: The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents. Accordingly, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.
    Type: Application
    Filed: December 30, 2015
    Publication date: December 21, 2017
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk KIM, Jong Min LEE, Sang Yun KIM, Sung Min BAE, Sung Youb JUNG, Se Chang KWON
  • Phtalazinone derivatives and manufacturing process thereof
    Patent number: 9844550
    Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 19, 2017
    Assignee: ILDONG PHARM CO., LTD
    Inventors: Jae-Hoon Kang, Hong-Sub Lee, Yoon-Suk Lee, Joon-Tae Park, Kyung-Mi An, Jin-Ah Jeong, Kyung-Sun Kim, Jeong-Geun Kim, Chang-Hee Hong, Sun-Young Park, Dong-Keun Song, Yong-Don Yun
  • Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
    Patent number: 9833413
    Abstract: Disclosed is a pharmaceutical combination formulation comprising a first discrete part containing amlodipine and rosuvastatin and a second discrete part containing losartan, which exhibits improved dissolution rate and stability. The inventive combination formulation comprising amlodipine, losartan and rosuvastatin having different action mechanisms from one another can be effectively used to prevent or treat a cardiovascular disorder. Designed to minimize an interaction among active ingredients, the pharmaceutical combination formulation exhibits excellent storage stability and dissolution rates of amlodipine, losartan and rosuvastatin, and thus can be useful in pharmaceutical industries.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: December 5, 2017
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Ho Taek Im, Myoung Ki Jeong, Yong Il Kim, Jae Hyun Park, Jong Soo Woo, Hyuk Jun Cho
  • Sulfamate derivative compounds for use in treating or alleviating pain
    Patent number: 9834535
    Abstract: The present invention relates to sulfamate derivative compounds and a composition for treating and/or alleviating pain containing the sulfamate derivative compounds or a pharmaceutically acceptable salt thereof as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition for treating or alleviating pain containing a sulfamate derivative compound and/or a pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a method for treatment or alleviation of pain comprising administering a sulfamate derivative compound in a pharmaceutically effective amount to a subject in need of treatment or alleviation of pain; and a use of the sulfamate derivative compound or the pharmaceutically acceptable salt thereof in treating and/or alleviating pain, are provided.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: December 5, 2017
    Assignee: Bio-Pharm Solutions Co., Ltd.
    Inventor: Yong Moon Choi
  • Liquid formulation of long-acting insulin and insulinotropic peptide
    Patent number: 9833516
    Abstract: The present invention relates to a liquid formulation of a combination of long-acting insulin and insulinotropic peptide, comprising insulin which is a physiologically active peptide, insulinotropic peptide, and albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent; and a method for preparing the liquid formulation. The liquid formulation of the present invention does not contain a human serum albumin and potentially toxic factors to the body, and thus it has excellent storage stability for insulin conjugate and insulinotropic peptide conjugate at high concentration, without a risk of viral contamination.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: December 5, 2017
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Hyung Kyu Lim, Hyun Uk Kim, Mi Kyoung Lee, Jong Soo Lee, Sung Min Bae, Se Chang Kwon
  • A METHOD FOR PREPARING GADOBUTROL
    Publication number: 20170342038
    Abstract: The present disclosure relates to a novel method for preparing high-purity gadobutrol. The present disclosure can be easily applied to a large scale production because purity of intermediate can be managed via simple and mild process and accordingly, high-purity or ultra high-purity gadobutrol that has higher purity than previous gadobutrol can be prepared in high yield therethrough.
    Type: Application
    Filed: December 28, 2015
    Publication date: November 30, 2017
    Applicant: ST PHARM CO., LTD.
    Inventors: Geun Jho LIM, Sun Ki CHANG, Chang Ho BYEON, Hoe Jin YOON, Moon Soo Kim
  • PHARMACEUTICAL COMPOSITION COMPRISING AMIDE DERIVATIVE INHIBITING THE GROWTH OF CANCER CELLS AND NON-METALLIC SALT LUBRICANT
    Publication number: 20170340744
    Abstract: Disclosed is a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof and a non-metallic salt lubricant, which can be used as an effective cancer cell-growth inhibitor owing to its enhanced storage stability with no quality changes over time.
    Type: Application
    Filed: August 11, 2017
    Publication date: November 30, 2017
    Applicant: Hanmi Pharm. Co., Ltd.
    Inventors: Yong Il Kim, Kyeong Soo Kim, Jin Cheul Kim, Yo Han Kim, Jae Hyun Park, Jong Soo Woo
  • Bicyclic derivatives and pharmaceutical composition including the same
    Patent number: 9828366
    Abstract: The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the SGLT activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type I diabetes mellitus) and non-insulin-dependent diabetes (type II diabetes mellitus), diabetic complications, and obesity.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: November 28, 2017
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Ji Sook Kim, Won Jeoung Kim, Wook Jang, Ji Young Song, Moon Sub Lee, Nam Du Kim, Kwee Hyun Suh
  • BIOCOMPATIBLE COMPOSITION AND METHOD FOR PREPARING SAME
    Publication number: 20170335021
    Abstract: The present disclosure relates to a biocompatible composition and a method for preparing the same, and a hybrid composition of ?-glucan and hyaluronic acid is prepared by hybrid cross-linkage. The biocompatible composition of the present disclosure high stability against heat and bio-enzymes, and thus is capable of being used as a medical material.
    Type: Application
    Filed: June 23, 2015
    Publication date: November 23, 2017
    Applicant: INNO PHARM CO., LTD.
    Inventors: Jae Young LIM, Byoung-Chull CHUNG
  • Method for preparing calcobutrol
    Patent number: 9822084
    Abstract: Disclosed is a novel method of preparing highly pure calcobutrol using an intermediate (butrol) of gadobutrol without using highly pure gadobutrol. This method is capable of obtaining calcobutrol at high purity and high yield through a simple and environmentally friendly process, and thus can be easily applied to mass production.
    Type: Grant
    Filed: September 7, 2015
    Date of Patent: November 21, 2017
    Assignee: ST PHARM CO., LTD.
    Inventors: Geun Jho Lim, Sun Ki Chang, Chang Ho Byeon, Hoe Jin Yoon, Moon Soo Kim
  • SOLID PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE AND LOSARTAN
    Publication number: 20170326110
    Abstract: The present invention provides a pharmaceutical composition for the prevention or treatment of cardiovascular disorders containing losartan or a pharmaceutically acceptable salt thereof; amlodipine or a pharmaceutically acceptable salt thereof; a disintegrant; and a coating agent. The composition of the present invention, which has the best combination and optimum ratio of a disintegrant to a coating agent, shows sufficient strength and high dissolution rates under various pH environments, and thus, it is useful for the preparation of an excellent solid formulation exhibiting improved drug delivery efficiency and storage stability.
    Type: Application
    Filed: September 1, 2015
    Publication date: November 16, 2017
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Leedong ROH, Ho Taek IM, Young Su YOON, Yong II KIM, Jae Hyun PARK, Jong Soo WOO
  • Complex granule formulation having improved stability comprising levocetirizine and montelukast
    Patent number: 9801876
    Abstract: The present invention relates to a complex granule formulation comprising a first granular part comprising levocetirizine or its pharmaceutically acceptable salt, cyclodextrin or its derivative, and an alkalinizing agent; and a second granular part comprising montelukast or its pharmaceutically acceptable salt, cyclodextrin or its derivative, and an alkalinizing agent. This formulation can effectively inhibit the production of related compounds of levocetirizine and montelukast by allowing levocetirizine and montelukast to form clathrate complexes with cyclodextrin, and using an alkalinizing agent. This formulation not only shows increased stability and bioavailability, but also improves patient compliance owing to its effective masking of bitter taste.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: October 31, 2017
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Ho Taek Im, Taek Kwan Kwon, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Liquid formulation of long acting insulinotropic peptide conjugate
    Patent number: 9801950
    Abstract: The present invention relates to a liquid formulation of long-acting insulinotropic peptide conjugate, comprising a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: October 31, 2017
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Hyun Uk Kim, Hyung Kyu Lim, Sung Hee Hong, Dae Jin Kim, Sung Min Bae, Se Chang Kwon
  • USE OF A LONG ACTING GLP-1/GLUCAGON RECEPTOR DUAL AGONIST FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
    Publication number: 20170298117
    Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves in vivo sustainability and stability.
    Type: Application
    Filed: September 16, 2015
    Publication date: October 19, 2017
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Sang Youn HWANG, Jin Young KIM, Seung Su KIM, In Young CHOI, Sung Youb JUNG, Se Chang KWON
  • Method for delivering a peptide to a subject at a modulated rate via microcapsules of lactic-co-glycolic copolymer containing said peptide
    Patent number: 9789064
    Abstract: Micro-capsules for the slow release of drugs, consisting of a lactic-co-glycolic copolymer to which a plasticizer has been incorporated and which contain a drug of pharmaceutical interested within them.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: October 17, 2017
    Assignee: GP PHARM, S.A.
    Inventors: Antonio Parente Dueña, Josep Garcés Garcés, Angel Bonilla Muñoz, David Cunillera Colomé
  • Method for preparing lacosamide
    Patent number: 9790170
    Abstract: The present invention provides a novel method for preparing lacosamide with high chiral purity from D-serine. The method of the present invention can obtain lacosamide with high chiral purity in a high yield through a simple and environmentally-friendly process and thus can be easily applied to mass production.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: October 17, 2017
    Assignee: ST PHARM CO., LTD.
    Inventors: Geun Jho Lim, Sun Ki Chang, Jae Hun Kim, Jong Moon Park
  • Method for cultivation of for production of thymoquinone
    Patent number: 9776939
    Abstract: A method for cultivating Monarda fistulosa for production of thymoquinone includes planting seeds at rates between about 2.5 and about 5 pounds per acre, preferably about 4 pounds per acre. The heavy rate of planting produces plants bearing oil without weed contamination and reduces herbicide use due to production of natural herbicides by the monarda plants. Seeding and mowing the first season, and harvesting in seasons thereafter reduce costs. The method results in increased production of essential oils including thymoquinone and thymohydroquinone at levels up to about 40% or more of recovered oils, and which may be distilled from the plant.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: October 3, 2017
    Assignee: Prairie Pharms, LLC
    Inventor: William G. Rohlfsen